Assessment of Empagliflozin as Adjuvant Therapy in Patients With Ulcerative Colitis
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
This is a randomized, controlled study evaluating empagliflozin tablets administered daily
for 8 weeks. The purpose of the study is to evaluate the efficacy and safety of empagliflozin
in the treatment of mild to moderately active ulcerative colitis. Disease activity will be
measured using Mayo score for ulcerative colitis activity. Calculation of the score requires
patients to undergo colonoscopy at the start of the study and at week 8.